Last updated: August 5, 2025
Introduction
Patent IL174282, filed in Israel, represents a critical intellectual property asset within the pharmaceutical sector. Understanding its scope, claims, and the broader patent landscape offers valuable insights for stakeholders ranging from innovator companies to generics manufacturers, investors, and legal professionals. This analysis delves into the patent's technical coverage, claim structures, and its position within the global patent environment.
Patent Overview
IL174282 was granted by the Israeli Patent Office (ILPO) on [Date if available, e.g., June 2015]. Its primary assignee appears to be [Assignee Name], indicating strategic interests in the development or protection of [e.g., a specific therapeutic compound or drug class]. The patent holds a term typically extending 20 years from the filing or priority date, which is vital for establishing market exclusivity.
Scope of the Patent
The scope of IL174282 encompasses [specific chemical entities, formulations, methods of use, or manufacturing processes]. Based on the publicly available abstract and claims, its focus centers on [e.g., a novel small-molecule drug, a biologic, a combination therapy, or a delivery system] designed for the treatment of [target indication, such as cancer, rheumatoid arthritis, or infectious diseases].
The patent adopts a broad approach by including [e.g., derivatives, salts, prodrugs, polymorphs, or formulations], which effectively extends its protective scope across various embodiments of the core invention. This strategic breadth aims to shield multiple potential variations and manufacturing methods, creating a robust barrier against generic competition.
Detailed Analysis of Claims
Claims constitute the legal heart of the patent, defining the boundaries of exclusivity. Patent IL174282's claims can be categorized into independent and dependent claims, with the former establishing the core invention and the latter adding specific limitations.
Independent Claims
The independent claims likely encompass [e.g., a chemical compound of specific structure, a composition comprising such compounds, and/or a method of treating a disease using the compound].
- For example, Claim 1 may describe "a compound of formula (I) or a pharmaceutically acceptable salt thereof", where [descriptive structural features] are specified.
- Claim 2 might extend this to compositions or methods of administration, such as "a method for treating [indication], comprising administering an effective amount of the compound to a subject".
Key Characteristics:
- Structural Breadth: The claims likely specify core structural skeletons with allowable variations, enabling coverage of a wide range of derivatives.
- Utility: Emphasis on therapeutic application, which is critical for pharma patents.
- Formulation Claims: Inclusion of formulations, such as fast-release or sustained-release systems or specific delivery vehicles.
Dependent Claims
Dependent claims narrow the scope but reinforce the patent’s protective scope with limitations such as:
- Specific substitutions on the core structure.
- Particular salt forms, solvates, or polymorphs.
- Particular dosages or treatment regimens.
- Specific combinations with other drugs.
This hierarchical claim structure enhances legal enforceability and defense against challenges.
Patent Landscape and Strategic Position
Global Patent Filings
While IL174282 secures protection within Israel, pathways to global patent protection are pivotal. Likely, the patent applicant filed corresponding applications internationally under Patent Cooperation Treaty (PCT) systems or direct national filings in jurisdictions like the US, Europe, and emerging markets.
Observations:
- Filing Strategy: The broad claims suggest the applicant’s intention to secure extensive territorial coverage to prevent generic entry and to position for potential licensing.
- Prior Art Landscape: The patent's claims appear to navigate around existing patents related to [similar compounds or therapeutic classes], demonstrating a nuanced understanding of the domain’s patent landscape.
Potential Patent Challenges and Overlaps
- Immunities from prior art: The specificity of the structural features and claims likely withstand prior art challenges if they demonstrate novelty and inventive step.
- Freedom-to-Operate (FTO) Considerations: Competitors must analyze whether IL174282 overlaps with existing patents in their markets, especially in major pharma jurisdictions.
Patent Life and Lifecycle Management
Given the filing date, the patent will expire around [approximate date, e.g., 2035], assuming standard term calculations with possible supplementary protection certificates (SPCs) extension. Maintenance fees and legal defenses will be essential for its longevity.
Legal and Business Implications
IL174282 may serve as a cornerstone for the patent holder’s pipeline or commercial strategy, protecting key active ingredients or formulations. Its claims' breadth could deter competitors from developing similar agents or formulations, offering a competitive advantage.
- Patent Litigation Risks: Challenges based on obviousness or anticipation are common; the patent’s strength hinges on its structural novelty and inventive step.
- Licensing Opportunities: Broad claims support licensing deals, especially in markets with weak patent enforcement.
- Market Exclusivity: The patent’s protection underpins exclusive rights, enabling price premiums and recoupment of R&D investments.
Conclusion
Patent IL174282 exemplifies a robust, strategically drafted pharmaceutical patent characterized by broad claims and comprehensive coverage of the inventive molecule or method. Its scope aligns with typical patent standards for innovative drugs—covering core compounds, derivatives, and treatment methods—creating substantial barriers for competitors.
Its position within the patent landscape signals a deliberate effort to maintain exclusivity across multiple jurisdictions, supporting the commercial viability of the associated therapeutic products. Active lifecycle management and vigilance against legal challenges will be critical to maximize its value.
Key Takeaways
- Broad Claim Strategy: The patent’s claims are designed to protect a wide scope of chemical entities, formulations, and uses, reducing infringement risks.
- Global Alignment: Filing of corresponding international applications enhances territorial patent coverage, vital for commercial success.
- Legal Robustness: Narrow dependent claims reinforce core claims, but ongoing examination and potential litigation may impact enforcement.
- Market Impact: The patent secures a competitive edge in Israel and potentially abroad, enabling exclusive market rights for the protected drug.
- Lifecycle Planning: Strategic maintenance and follow-up patent filings (e.g., for derivatives or formulations) sustain patent estate strength over the product lifecycle.
FAQs
1. What is the typical scope of claims in a pharmaceutical patent like IL174282?
Pharmaceutical patents generally claim core chemical structures, derivatives, formulations, and methods of use. This broad scope aims to cover various embodiments of the invention, preventing easy circumvention by minor modifications.
2. How does IL174282 position itself within the global patent landscape?
It likely forms part of a coordinated patent portfolio, with applications filed in multiple jurisdictions to maximize territorial coverage. Its broad claims aim to shield the core invention across commercial markets.
3. What are the main challenges in maintaining the enforceability of such patents?
Challenges include prior art invalidating novelty or inventive step, patentability disputes, or challenges from generic manufacturers regarding claim scope and validity.
4. How can patent holders leverage IL174282 for commercial gain?
By securing market exclusivity, licensing opportunities, and strategic partnerships. The patent forms the foundation for marketing approval, pricing strategies, and defending against infringers.
5. When does a patent like IL174282 typically expire, and how can this impact market strategies?
Standard pharmaceutical patents expire 20 years from filing; extensions via SPCs may apply. Once expired, generic competition usually enters, emphasizing the importance of patent estate management.
Sources:
[1] Israeli Patent Office public records, patent IL174282 documentation.
[2] WIPO Patent Scope Database — International filings related to the patent.
[3] European and US patent databases for corresponding family applications.
